EAE/MOG Peptide Mouse Model for Multiple Sclerosis (MS)

EAE/MOG Peptide Mouse Model for Multiple Sclerosis

Multiple sclerosis (MS) is a chronic neurodegenerative and inflammatory disease of the central nervous system (CNS) that represents one of the most prevalent human autoimmune diseases. MS shows striking similarities with experimental autoimmune encephalomyelitis (EAE), an acute or chronic-relapsing, acquired inflammatory and demyelinating autoimmune disease. EAE can be induced in susceptible mice strains by administration of peptides derived from myelin proteins such as myelin oligodendrocyte glycoprotein 35-55 (MOG35-55) that are expressed in the CNS and cause lesions that resemble many features of MS. Many other physical features including limp tail, hind and/or front legs weakening or complete paralysis are observed and scores as indexes of disease severity. EAE models are known to be well-suited tools for experimentally addressing mechanisms that cause autoimmune pathology of the CNS and for evaluating the therapeutic potential of test compounds for curing or preventing MS. Increasingly, EAE in C57BL/6J mice has become the most desired model.

Washington Biotechnology, Inc. has validated in C57BL/6J mice an EAE model that showed over a 32 day period relapsing-remitting disease episodes that are prevalent in approximately 85% of MS cases (see table and graph below).

Summary of chemicals used for EAE induction, Mean of maximum score obtained, mice number/group, age and day of disease onset

Graph showing progression of EAE clinical signs in C57BL/6J strain as determined by severity score indexes